The Effects of Waning of Botulinum Toxin in the Treatment of Cervical Dystonia

Launched by WESTERN UNIVERSITY, CANADA · Mar 13, 2025

Keywords

ClinConnect Summary

Cervical dystonia (CD) is a disabling and often painful condition clinically characterized by abnormal neck and head postures and movements often associated with tremor and chronic pain. Botulinum toxin type A (BoNT-A) is an effective and safe first-line therapy for CD. However, in a recent patient perspective survey, symptom re-emergence between injections (a mean 10.5 weeks) was reported in 88% of patients with a waning time of ≤8 weeks in one-third of patients. Waning treatment effects prior to re-injection reduces quality of life as 47% of patients are somewhat satisfied, and 39% were not...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 18 years or above with a diagnosis of isolated CD
• • Experience efficacious relief with a waning time of ≤8 weeks post-injection
• • Must have received the same dose and injection pattern of onaBoNT-A or incoBoNT-A for at least 3 injection cycles prior to study initiation with an injection cycle of 12 weeks
• Exclusion Criteria:
• • Require a total dose \<80 U or \>300 U ona/incoBoNT-A
• • Pure reterocollis or suspected secondary non-responsiveness
• • No interest in switching between BoNT-A formulations
• • Prolonged history of dysphagia
• • History of poor response to BoNT-A or BoNT-B
• • Inability to complete study visits or sign informed consent
• • Pregnancy
• • Known resistance or contradictions to any BoNT-A
• • Known hypersensitivity to BoNT-A or related compound

Trial Officials